Stronger Hearts for Childhood Cancer Survivors
Pediatric oncologists and cardiologists collaborate on reducing cardiotoxic effects of cancer treatment.
Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments
The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.
Researchers discover molecular signature for aggressive thyroid cancer
A Vanderbilt study found that a molecular signature that predicts aggressive thyroid cancer could help guide treatment approaches for patients.
Being treated for childhood cancer set Jason Schwartz on the path to his life’s work: treating childhood cancer
At the ripe age of 13, Jason Schwartz made a life-changing decision. Amid cancer treatment for Acute Lymphoblastic Leukemia (ALL), Schwartz was handed an incredible gift that would fuel his life’s work.
AI to Address Questions Left by Lung Screenings
Research team refines method for diagnosis of indeterminant lung nodules using artificial intelligence and advanced learning.
Clinical trial shows efficacy for atezolizumab combined with carboplatin
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.
Nicole Kidman and Keith Urban gift supports breast cancer clinical trials at Vanderbilt-Ingram Cancer Center
Nicole Kidman and Keith Urban have made a generous financial gift to Vanderbilt-Ingram Cancer Center in support of clinical trials for new and better therapies for breast cancer.
Liquid biopsy test may detect early-stage and low DNA-shedding cancers
Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.
Study discovers that tumor mutation burden predicts survival outcome
The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.
